TEVA enters September with a quietly shifting short book, a 5% weekly price drop, and options traders showing their most defensive posture in months — all against a Street consensus that remains firmly bullish.
The clearest tension this week is in the gap between price action and analyst conviction. The stock fell 5% over the past week to $36.19, reversing much of a 3.4% monthly gain. Yet the analyst community remains constructively positioned. The most recent target raise came from Barclays in mid-August, lifting to $42 while maintaining Overweight. Piper Sandler followed a post-earnings bump to $44 in late July. The Street consensus stands at buy, with four outperform ratings and one hold — and every recent analyst move has been a target raise, not a cut. At $36.19 against a cluster of targets in the $42–$45 range, the implied upside from current levels runs between 15% and 25%.
Where the Street is optimistic, options traders are hedging. The put/call ratio has climbed to 0.42 — its highest level in roughly six weeks and nearly 1.7 standard deviations above its 20-day mean of 0.37. The move has been gradual but sustained: the PCR spent most of August in a tight band around 0.35–0.37, before stepping up noticeably in the final week of the month. That suggests protection-buying rather than a sudden sentiment reversal, but the drift is real. The 52-week high is 0.76, so the reading is far from an extreme — this is caution, not panic.
Short interest tells a broadly neutral story, with one notable undercurrent worth tracking. The short book has grown roughly 19% from its late-July base of around 31.4 million shares to 37.4 million shares now — a meaningful build over five weeks. The weekly change is nearly flat, suggesting the rebuild has paused rather than accelerated. Borrow conditions offer no squeeze mechanics: availability runs at nearly 1,864% of short interest, meaning shares to borrow are abundant by any measure, and the cost to borrow is just 0.44% annually — cheap even after a 20% weekly uptick. The ORTEX short score of 42.8, in the middle of the range, corroborates the picture: elevated positioning relative to recent history, but no structural pressure on short sellers.
On the fundamental side, bulls point to the Emalex acquisition, whose lead asset Ecopipam targets Tourette Syndrome with a profile that avoids the side-effect burden of current treatments — an addressable market that analysts flag could support $500 million to $1 billion in peak sales through 2034 exclusivity. Teva's China biosimilar ambitions add another diversification angle. Bears flag revenue headwinds expected near-term and heavy reliance on the neuroscience segment to carry forward growth, with the anti-IL-15 pipeline facing a competitive autoimmune market where differentiation on efficacy will be essential. The trailing P/E of 13.7x and EV/EBITDA of 11x are modest by pharma standards, consistent with the debt overhang that has defined Teva's re-rating story for several years. The dividend was suspended in 2017 and has not returned, so income is not a driver here.
Institutional ownership clusters around Israeli financial groups — Harel, Phoenix, Menora, Migdal — and large global passives including BlackRock and Norges Bank, each holding roughly 6% of shares. The ownership base is relatively sticky. On the insider side, the most recent SEC filings show the Chief Accounting Officer exercised options and sold the resulting shares on August 21, a routine exercise-and-sell with no open-market purchase to offset it. Net insider value over the past 90 days runs at roughly -$371,000 — small in absolute terms and driven by a single compensation-mechanics transaction rather than any discretionary selling signal.
The next earnings event is scheduled for November 4. The July 29 print produced an 11.8% single-day gain and a 9.6% five-day follow-through — a notably strong post-earnings pattern that bulls will point to when the print approaches. For now, the setup to watch is whether the PCR drift continues to push toward its summer highs, and whether the short book — which has rebuilt steadily since July — finds fresh conviction or plateaus around current levels as the stock digests the gap between its $36 price and the analyst target zone north of $42.
See the live data behind this article on ORTEX.
Open TEVA on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
